Maxim Group Cuts Cryo-Cell International (NYSEAMERICAN:CCEL) Price Target to $8.50

Cryo-Cell International (NYSEAMERICAN:CCEL) had its price target trimmed by Maxim Group from $9.00 to $8.50 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Cryo-Cell International Price Performance

Shares of NYSEAMERICAN:CCEL opened at $7.03 on Tuesday. The firm has a market capitalization of $56.66 million, a price-to-earnings ratio of -6.63 and a beta of 0.53. Cryo-Cell International has a 52-week low of $5.35 and a 52-week high of $9.50.

Cryo-Cell International Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Friday, February 14th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 14.22%. The ex-dividend date of this dividend was Friday, February 14th. Cryo-Cell International’s dividend payout ratio is presently -94.34%.

Hedge Funds Weigh In On Cryo-Cell International

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in Cryo-Cell International by 68.5% during the 3rd quarter. Geode Capital Management LLC now owns 39,860 shares of the company’s stock valued at $254,000 after acquiring an additional 16,203 shares during the period. Rowlandmiller & PARTNERS.ADV purchased a new position in Cryo-Cell International during the 4th quarter valued at about $107,000. Northern Trust Corp boosted its holdings in Cryo-Cell International by 78.2% during the 4th quarter. Northern Trust Corp now owns 38,902 shares of the company’s stock valued at $288,000 after acquiring an additional 17,066 shares during the period. Topline Capital Management LLC purchased a new position in Cryo-Cell International during the 4th quarter valued at about $354,000. Finally, CreativeOne Wealth LLC purchased a new position in Cryo-Cell International during the 4th quarter valued at about $113,000. 10.44% of the stock is currently owned by hedge funds and other institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.